(BUSINESS WIRE)--A breast cancer vaccine currently being tested in a Phase II trial has demonstrated to be safe and well tolerated in patients according to a paper to be published in the Journal of Clinical Oncology.
The therapeutic breast cancer vaccine AE37 uses a peptide antigen (immune-stimulating fragment) of a cancer gene known as HER-2/neu. This gene/protein is present in many types of cells, but it is over-expressed in a high proportion of breast cancers as well as many others. The vaccine is being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex.
